Dyslipidemia is one of the most important risk factors for the cardiovascular system. A large number of clinical studies have confirmed that the use of statins to reduce cholesterol levels can reduce the incidence and fatality and disability of atherosclerotic cardiovascular disease. However, recent studies have shown that patients with dyslipidemia face a high risk of cardiovascular remaining even after intensive cholesterol-lowering therapy with high-dose statins[1]While in patients with type 2 diabetes, obesity, metabolic syndrome, and/or cardiovascular disease, elevated triglycerides (TG) and decreased high-density lipoprotein cholesterol (HDL-C) are the major dyslipidemia phenotypes that constitute the risk of cardiovascular retention[2]。 Therefore, while paying attention to the harm of hypercholesterolemia and emphasizing the cornerstone position of statins in the prevention and treatment of cardiovascular diseases, full attention should also be paid to the screening and intervention of other types of dyslipidemia such as TG increase. In order to increase the importance of domestic clinicians on the increase of TG and cardiovascular residual risk, and promote the standardized management of hyperTGemia, the Evidence-Based Medicine Review Expert Group of Cardiovascular Disease Branch of Chinese Medical Association, together with the Cardiovascular and Cerebrovascular Disease Professional Committee of Chinese Gerontological Society, organized experts in related fields to formulate this consensus.
暂无数据
